MedTrace Logo

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2018-05-02

Study results available
· View outcomes & findings →

Summary

The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.

Conditions

  • NAFLD

Interventions

DRUG

Leu-Met-Sil 0.5

NS-0200 low dose

DRUG

Leu-Met-Sil 1.0

NS-200 high dose

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • NuSirt Biopharma

    lead INDUSTRY

Principal Investigators

  • Orville Kolterman, MD · NuSirt Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-19
Primary Completion
2016-11-30
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546609 on ClinicalTrials.gov